Celltrion Healthcare wins Remsima order in France, Italy

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for hospital procurement by France's General Agency for Health Equipment and Products (AGEPS).

AGEPS is responsible for pharmaceutical procurement for the Public Assistance Hospitals of Paris (APHP), a consortium of university hospitals in the Paris and Île-de-France regions. As a result, Celltrion Healthcare is expected to supply Remsima for three years from this month until 2026.

Furthermore, the company has also secured a successful bid for infliximab in the central Umbria region of Italy. Celltrion Healthcare previously won another autoimmune disease treatment Yuflyma in government tenders in five Italian regions during the third quarter.

Celltrion Healthcare anticipates cost improvements after the merger with Celltrion Inc. and plans to expand its market share for Remsima in Europe based on competitive pricing.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com